title: Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes.
abstract: Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug-drug interaction (DDIs) with metabolic and transport proteins in sandwich-cultured human hepatocytes (SCHH). Tolvaptan was incubated with SCHH and quantified by LC-MS/MS. Pioglitazone, verapamil, MK-571 and elacridar were used as inhibitors to investigate mechanisms of transport and metabolism of tolvaptan and metabolites. Taurocholate (TCA), pravastatin, digoxin, and metformin were used as transporter probes to investigate which transport proteins were inhibited by tolvaptan and metabolites. Cellular accumulation of tolvaptan (0.15-50 μM), DM-4103 and DM-4107 in SCHH was concentration dependent. Tolvaptan accumulation (15 μM) in SCHH was not altered markedly by 50 μM pioglitazone, verapamil or MK-571, or 10 μM elacridar. Co-incubation of tolvaptan with pioglitazone, verapamil, MK-571 and elacridar reduced DM-4107 accumulation by 45.6, 79.8, 94.5 and 23.0%, respectively, relative to control. Co-incubation with increasing tolvaptan concentrations (0.15-50 μM) decreased TCA (2.5 μM) cell+bile accumulation and the TCA biliary excretion index (BEI; from 76% to 51%), consistent with inhibition of the bile salt export pump (BSEP). Tolvaptan (15 μM) had no effect on the cellular accumulation of 2.5 μM pravastatin or metformin. Digoxin cellular accumulation increased and the BEI of digoxin decreased from 23.9% to 8.1% in the presence of 15 μM tolvaptan, consistent with inhibition of P-glycoprotein (P-gp). In summary, SCHH studies revealed potential metabolic- and transporter-mediated DDIs involving tolvaptan and metabolites.
authors.affiliation: University of North Carolina at Chapel Hill;
authors.forename: Yang
authors.initials: Y
authors.lastname: Lu
authors.affiliation: University of North Carolina at Chapel Hill;
authors.forename: Jason R
authors.initials: JR
authors.lastname: Slizgi
authors.affiliation: Qualyst Transporter Solutions;
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Brouwer
authors.affiliation: Qualyst Transporter Solutions;
authors.forename: Robert L St
authors.initials: RL
authors.lastname: Claire
authors.affiliation: Qualyst Transporter Solutions;
authors.forename: Kimberly M
authors.initials: KM
authors.lastname: Freeman
authors.affiliation: Otsuka PDC.
authors.forename: Maxwell
authors.initials: M
authors.lastname: Pan
authors.affiliation: Otsuka PDC.
authors.forename: William J
authors.initials: WJ
authors.lastname: Brock
authors.affiliation: University of North Carolina at Chapel Hill; kbrouwer@unc.edu.
authors.forename: Kim L
authors.initials: KL
authors.lastname: Brouwer
keywords: Transporter-mediated drug/metabolite disposition; hepatocytes